Strong Revenue Growth#
UK-based Aptamer Group, known for developing synthetic binders, has announced a 27% increase in revenue for the first half of the year compared to the same period last year. This growth is largely attributed to new and repeat contracts with pharmaceutical companies, particularly in the area of radioligand therapy, which is a treatment method that uses radioactive substances to target cancer cells.
Improved Financial Performance#
The company reported a narrowed adjusted EBITDA loss of £1.0 million, indicating that while they are still operating at a loss, their financial situation is improving as revenue rises and costs are kept under control. Aptamer achieved a gross profit of £460,000 during this half-year period, reflecting the positive impact of their contracts.
Fundraising Efforts#
To further support its growth, Aptamer has initiated an Accelerated Book Build, aiming to raise at least £3.75 million. This funding is expected to extend the company’s cash runway, allowing it to operate through 2028. The company also reported a first-half EBIT (Earnings Before Interest and Taxes) loss of £1.24 million and basic earnings per share of 0.04 pence.
Future Plans#
Aptamer is focused on transforming its asset portfolio into recurring revenue streams through royalties and licensing agreements. They are targeting the release of in vivo data, which refers to data collected from living organisms, for their radiopharmaceutical pipeline by the end of 2026. Additionally, the company plans to enhance its manufacturing capacity and conduct quality audits to ensure the supply of licensed assets and improve profit margins.